ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2341

The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis

Claire Deakin1, John Bowes2, Lucy Marshall1, Cerise Johnson1, Gulnara Mamyrova3, Rodolfo Curiel4, Kelly A. Rouster-Stevens5, Heinrike Schmeling6, Adam Huber7, Brian M. Feldman8, Ann M Reed9, Lauren M. Pachman10, Soumya Raychaudhuri11, Stephen Eyre12 and Lucy R Wedderburn1, 1Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, 2Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 3Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, 4Department of Rheumatology, George Washington University, Washington, DC, 5Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, 6Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, 7IWK Health Centre, Halifax, NS, Canada, 8Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 9Rheumatology, Duke University, Durham, NC, 10Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 11Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 12Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Aging, genetics, GWAS, juvenile dermatomyositis and juvenile myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Juvenile dermatomyositis (JDM) is a rare, severe autoimmune disease characterized by muscle weakness and rash. Clinical features of JDM are heterogeneous, and can include serious complications such as calcinosis, ulceration, treatment-resistant rash and involvement of major organs, including gut, lungs and brain. While JDM and adult-onset dermatomyositis (DM) share similar clinical and biological features, there are differences in prevalence of clinical features. Cancer development is a major complication of DM, but not JDM. Conversely, calcinosis is a major cause of morbidity in JDM, but has a low occurrence in DM. The prevalence of myositis-specific autoantibodies (MSA), which are linked to different clinical features of disease, also differs between the adult and juvenile forms of the disease. These differences in the distribution of MSA and clinical features suggest an influential role for age of disease onset on the pathogenesis of disease.

Methods:

Caucasian JDM cases from the UK (n=312) were genotyped using the Illumina HumanCoreExome chip. Caucasian control data (n=2808) were obtained from the Wellcome Trust Case Control Consortium. Following quality control, classical human leukocyte antigen (HLA) alleles and HLA amino acids were imputed using SNP2HLA. Logistic, linear and Cox regression were performed using PLINK and R package GenABEL, with adjustment for the first two principal components. Genome-wide significant association was set at P < 5.0×10-8 and suggestive association at P < 1.0×10-5. We subsequently built an international consortium to create a replication cohort of Caucasian cases from North America (n=475).

Results:

Case-control analyses confirmed involvement of HLA including multiple loci within HLA-C (p = 1.35×10‑8, OR = 2.49, 95% CI = 1.82 – 3.42) and HLA-DRB1 (p = 2.73×10-8, OR = 0.56, 95% CI = 0.46-0.69) at genome-wide levels of statistical significance. Outside the HLA region there was suggestive evidence of association at ZNF337 (p = 7.49×10-6, OR = 1.81, 95% CI = 1.40-2.34), a zinc finger protein of unknown function. Analyses of association with age of disease onset did not implicate HLA involvement, suggesting the associations between HLA and JDM/DM are not influenced by age. Analysis of age of onset as a quantitative trait revealed suggestive associations at PDE1A (p = 1.56×10‑6, β = -1.61, 95% CI = -2.26- -0.97) and AGPAT3 (p = 2.26×10-6, β = 1.63, 95% CI = 0.97-2.30), genes involved in regulating intracellular cyclic nucleic acid concentrations and phospholipid biosynthesis/ Golgi-to-endoplasmic reticulum retrograde transport, respectively. In addition, we now have a replication cohort via our international consortium to validate these findings.

Conclusion:

This study has confirmed findings from previously published GWAS and Immunochip studies of JDM and DM concerning HLA involvement. Additionally, analyses of associations with age of JDM onset identified novel loci, PDE1A and AGPAT3, which if validated could suggest novel processes involved in pathogenesis. These findings will be confirmed in an independent replication cohort. Together with these validation samples, this study will be the largest GWAS of JDM to date.


Disclosure: C. Deakin, None; J. Bowes, None; L. Marshall, None; C. Johnson, None; G. Mamyrova, Cure JM, 2; R. Curiel, Cure JM, 2,BMS, 2; K. A. Rouster-Stevens, None; H. Schmeling, None; A. Huber, None; B. M. Feldman, None; A. M. Reed, None; L. M. Pachman, None; S. Raychaudhuri, Pfizer Inc, 2,Roche Pharmaceuticals, 2; S. Eyre, None; L. R. Wedderburn, None.

To cite this abstract in AMA style:

Deakin C, Bowes J, Marshall L, Johnson C, Mamyrova G, Curiel R, Rouster-Stevens KA, Schmeling H, Huber A, Feldman BM, Reed AM, Pachman LM, Raychaudhuri S, Eyre S, Wedderburn LR. The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-interaction-between-genetic-risk-factors-and-age-of-disease-onset-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-interaction-between-genetic-risk-factors-and-age-of-disease-onset-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology